Abstract
Objectives and methods
We reviewed the outcomes of 77 episodes of CD19 CAR-T therapy in 67 patients with
B cell hematological malignancies from October 2016 to January 2020. Factors related
to the grade of cytokine release syndrome (CRS) were explored by multivariate analysis,
nonparametric test was conducted to explore the correlation between CRS and response.
Kaplan–Meier curves were used to indicate survival profiles, and the correlation between
CRS and survival was determined by the log-rank test.
Results
The rate of complete remission (CR) was 74.0% (57/77). CRS of any grade occurred in
68 of 77 episodes (grade 1: 32.5%, grade 2: 24.7%, grade 3: 22.1%, grade 4: 6.5%,
grade 5: 2.6%). Patients with a history of transplantation had less severe CRS, and
dose escalation-based infusion reduced the severity of CRS. Severe CRS was related
to a higher CR rate but had no significant impact on event-free survival (EFS), relapse-free
survival (RFS), or overall survival (OS).
Conclusion
As a common adverse reaction of CAR-T therapy, the severity of CRS can be alleviated
by dose escalation infusion, a history of transplantation was correlated with less
severe CRS. Severe CRS was related to better response but was unrelated to long-term
survival.
Keywords
To read this article in full you will need to make a payment
Purchase one-time access:
Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online accessOne-time access price info
- For academic or personal research use, select 'Academic and Personal'
- For corporate R&D use, select 'Corporate R&D Professionals'
Subscribe:
Subscribe to Transfusion and Apheresis ScienceAlready a print subscriber? Claim online access
Already an online subscriber? Sign in
Register: Create an account
Institutional Access: Sign in to ScienceDirect
References
- Improved survival for children and adolescents with acute lymphoblastic leukemia between 1990 and 2005: a report from the children's oncology group.J Clin Oncol. 2012; 30: 1663-1669https://doi.org/10.1200/JCO.2011.37.8018
- Improvement in survival in younger patients with acute lymphoblastic leukemia from the 1980s to the early 21st century.Blood. 2009; 113: 1408-1411https://doi.org/10.1182/blood-2008-06-164863
- The myth of the second remission of acute leukemia in the adult.Blood. 2013; 121: 1077-1082https://doi.org/10.1182/blood-2012-08-234492
- Chimeric antigen receptor–modified T cells in chronic lymphoid leukemia.N Engl J Med. 2011; 365: 725-733https://doi.org/10.1056/nejmoa1103849
- Chimeric antigen receptor T cells persist and induce sustained remissions in relapsed refractory chronic lymphocytic leukemia.Sci Transl Med. 2015; 7: 1-13https://doi.org/10.1126/scitranslmed.aac5415
- Anti-CD19 CAR T-cell therapy for B-cell non-hodgkin lymphoma.Transfus Med Rev. 2020; 34: 29-33https://doi.org/10.1016/j.tmrv.2019.08.003
- Axicabtagene ciloleucel CAR T-cell therapy in refractory large B-cell lymphoma.N Engl J Med. 2017; 377: 2531-2544https://doi.org/10.1056/NEJMoa1707447
- Tisagenlecleucel in children and young adults with B-cell lymphoblastic leukemia.N Engl J Med. 2018; 378: 439-448https://doi.org/10.1056/NEJMoa1709866
- Long-term follow-up of CD19 CAR therapy in acute lymphoblastic leukemia.N Engl J Med. 2018; 378: 449-459https://doi.org/10.1056/NEJMoa1709919
- Cytokine release syndrome.J Immunother Cancer. 2018; 6: 56https://doi.org/10.1186/s40425-018-0343-9
- The incidence of cytokine release syndrome and neurotoxicity of CD19 chimeric antigen receptor-T cell therapy in the patient with acute lymphoblastic leukemia and lymphoma.Cytotherapy. 2020; 22: 214-226https://doi.org/10.1016/j.jcyt.2020.01.015
- Early and late hematologic toxicity following CD19 CAR-T cells.Bone Marrow Transpl. 2019; 54: 1643-1650https://doi.org/10.1038/s41409-019-0487-3
- Coagulation disorders after chimeric antigen receptor T cell therapy: analysis of 100 patients with relapsed and refractory hematologic malignancies.Biol Blood Marrow Transpl. 2020; 26: 865-875https://doi.org/10.1016/j.bbmt.2019.11.027
- Treatment response, survival, safety, and predictive factors to chimeric antigen receptor T cell therapy in Chinese relapsed or refractory B cell acute lymphoblast leukemia patients.Cell Death Dis. 2020; 11: 207https://doi.org/10.1038/s41419-020-2388-1
- Toci or not toci: innovations in the diagnosis, prevention, and early management of cytokine release syndrome.Leuk Lymphoma. 2021; 62: 2600-2611https://doi.org/10.1080/10428194.2021.1924370
- ASTCT consensus grading for cytokine release syndrome and neurologic toxicity associated with immune effector cells.Biol Blood Marrow Transpl. 2019; 25: 625-638https://doi.org/10.1016/j.bbmt.2018.12.758
- Hepatotoxicity of chemotherapy.Expert Opin Drug Saf. 2002; 1: 339-353https://doi.org/10.1517/14740338.1.4.339
- High efficacy and safety of low-dose CD19-directed CAR-T cell therapy in 51 refractory or relapsed B acute lymphoblastic leukemia patients.Leukemia. 2017; 31: 2587-2593https://doi.org/10.1038/leu.2017.145
- Potent anti-leukemia activities of humanized CD19-targeted Chimeric antigen receptor T (CAR-T) cells in patients with relapsed/refractory acute lymphoblastic leukemia.Am J Hematol. 2018; 93: 851-858https://doi.org/10.1002/ajh.25108
- T cells expressing CD19 chimeric antigen receptors for acute lymphoblastic leukaemia in children and young adults: a phase 1 dose-escalation trial.Lancet. 2015; 385: 517-528https://doi.org/10.1016/s0140-6736(14)61403-3
- KTE-X19 CAR T-cell therapy in relapsed or refractory mantle-cell lymphoma.N Engl J Med. 2020; 382: 1331-1342https://doi.org/10.1056/NEJMoa1914347
- Lisocabtagene maraleucel for patients with relapsed or refractory large B-cell lymphomas (TRANSCEND NHL 001): a multicentre seamless design study.Lancet. 2020; 396: 839-852https://doi.org/10.1016/s0140-6736(20)31366-0
- Tisagenlecleucel in adult relapsed or refractory diffuse large B-cell lymphoma.N Engl J Med. 2019; 380: 45-56https://doi.org/10.1056/NEJMoa1804980
- Cytokine release syndrome with chimeric antigen receptor T cell therapy.Biol Blood Marrow Transpl. 2019; 25: e123-e127https://doi.org/10.1016/j.bbmt.2018.12.756
- A retrospective comparison of allogenic and autologous chimeric antigen receptor T cell therapy targeting CD19 in patients with relapsed/refractory acute lymphoblastic leukemia.Bone Marrow Transpl. 2019; 54: 1208-1217https://doi.org/10.1038/s41409-018-0403-2
- Allogeneic CD19-CAR-T cell infusion after allogeneic hematopoietic stem cell transplantation in B cell malignancies.J Hematol Oncol. 2017; 10: 35https://doi.org/10.1186/s13045-017-0405-3
- Donor-derived CD19-targeted T cells cause regression of malignancy persisting after allogeneic hematopoietic stem cell transplantation.Blood. 2013; 122: 4129-4139https://doi.org/10.1182/blood-2013-08-519413
- Combining CD19 redirection and alloanergization to generate tumor-specific human T cells for allogeneic cell therapy of B-cell malignancies.Cancer Res. 2010; 70: 3915-3924https://doi.org/10.1158/0008-5472.CAN-09-3845
- CAR T cell-induced cytokine release syndrome is mediated by macrophages and abated by IL-1 blockade.Nat Med. 2018; 24: 731-738https://doi.org/10.1038/s41591-018-0041-7
- Monocyte-derived IL-1 and IL-6 are differentially required for cytokine-release syndrome and neurotoxicity due to CAR T cells.Nat Med. 2018; 24: 739-748https://doi.org/10.1038/s41591-018-0036-4
- Monocyte-mediated T-cell suppression and augmented monocyte tryptophan catabolism after human hematopoietic stem-cell transplantation.Blood. 2005; 105: 4127-4134https://doi.org/10.1182/blood-2004-05-1726
- Chimeric antigen receptor T cells for sustained remissions in leukemia.N Engl J Med. 2014; 371: 1507-1517https://doi.org/10.1056/NEJMoa1407222
- CD19 CAR-T cells of defined CD4+:CD8+ composition in adult B cell ALL patients.J Clin Investig. 2016; 126: 2123-2138https://doi.org/10.1172/JCI85309
- Efficacy and toxicity management of 19-28z CAR T cell therapy in B cell acute lymphoblastic leukemia.Sci Transl Med. 2014;
- Kinetics and biomarkers of severe cytokine release syndrome after CD19 chimeric antigen receptor-modified T-cell therapy.Blood. 2017; 130: 2295-2306https://doi.org/10.1182/blood-2017-06-793141
- Incidence and risk factors associated with a syndrome of persistent cytopenias after CAR-T cell therapy (PCTT).Leuk Lymphoma. 2019; 61: 1-4
- Clinical and biological correlates of neurotoxicity associated with CAR T-cell therapy in patients with B-cell acute lymphoblastic leukemia.Cancer Discov. 2018; 8: 958-971https://doi.org/10.1158/2159-8290.CD-17-1319
- Intent-to-treat leukemia remission by CD19 CAR T cells of defined formulation and dose in children and young adults.Blood. 2017; 129: 3322-3331https://doi.org/10.1182/blood-2017-02-769208
- Platelet activation determines angiopoietin-1 and VEGF levels in malaria: implications for their use as biomarkers.PLoS One. 2014; 8e64850https://doi.org/10.1371/journal.pone.0064850
- Interleukin-6 induces oxidative stress and endothelial dysfunction by overexpression of the angiotensin II type 1 receptor.Circ Res. 2004; 94: 534-541https://doi.org/10.1161/01.RES.0000115557.25127.8D
- Cytokine release syndrome: who is at risk and how to treat.Best Pract Res Clin Haematol. 2017; 30: 336-340https://doi.org/10.1016/j.beha.2017.09.002
- Recent advances in CAR T-cell toxicity: mechanisms, manifestations and management.Blood Rev. 2019; 34: 45-55https://doi.org/10.1016/j.blre.2018.11.002
- Factors associated with durable EFS in adult B-cell ALL patients achieving MRD-negative CR after CD19 CAR T-cell therapy.Blood. 2019; 133: 1652-1663https://doi.org/10.1182/blood-2018-11-883710
- Anti-CD19 chimeric antigen receptor-modified T-cell therapy bridging to allogeneic hematopoietic stem cell transplantation for relapsed/refractory B-cell acute lymphoblastic leukemia: an open-label pragmatic clinical trial.Am J Hematol. 2019; 94: 1113-1122https://doi.org/10.1002/ajh.25582
- Exploring the dilemma of allogeneic hematopoietic cell transplantation after chimeric antigen receptor T cell therapy: to transplant or not? Biol blood marrow transplant.Biol Blood Marrow Transplant. 2020; 26: e183-e191https://doi.org/10.1016/j.bbmt.2020.04.003
Article info
Publication history
Published online: May 31, 2022
Accepted:
May 29,
2022
Received in revised form:
May 21,
2022
Received:
February 23,
2022
Identification
Copyright
© 2022 Elsevier Ltd. All rights reserved.
